Cingulate (CING) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cingulate (CING) has outperformed PDS Biotechnology (PDSB) over the past year, gaining 15.9% versus a gain of 2.0%. PDS Biotechnology is the larger company by market cap ($100.0 million vs $71.1 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | PDSB |
|---|---|---|
| Share price | $4.89 | $1.38 |
| Market cap | $71.11M | $100.01M |
| 1-day change | +0.20% | +35.29% |
| YTD return | +12.44% | +32.47% |
| 1-year return | +15.91% | +2.00% |
| 5-year return | — | -91.73% |
| EPS (TTM) | $-3.51 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.89 | $1.55 |
| 52-week low | $3.16 | $0.195 |
| Distance from 52-week high | -58.87% | -10.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +333.54% | +262.32% |
| Average volume | 137.37K | 23.24M |
| Shares outstanding | 14.54M | 72.47M |
| Employees | 14 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed PDSB by 13.9 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CING vs PDSB FAQ
Which is bigger, Cingulate or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $71.11M for Cingulate (CING).
Which stock has performed better over the past year, CING or PDSB?
CING returned +15.91% over the past 12 months, compared with +2.00% for PDSB (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.